Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases

INTRODUCTION: To assess the safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab(®) (Intas Pharmaceuticals, Ahmedabad, India) in chorioretinal disorders under real-world conditions. METHODS: This was a multicenter, retrospective chart review which included patients from 15 cen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ophthalmol Ther
Autors principals: Chakraborty, Debdulal, Stewart, Michael W., Sheth, Jay U., Sinha, Tushar K., Boral, Subhendu, Das, Arnab, Mondal, Soumen, Mukherjee, Angshuman
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8079600/
https://ncbi.nlm.nih.gov/pubmed/33864599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40123-021-00345-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars